Biogen Inc (BIIB) Return on Assets ROA from the third quarter of 2026 to third quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
Biogen Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Biogen Inc 's ROA in the third quarter of 2026? Biogen Inc achieved a return on average assets (ROA) of 1.12 % in its third quarter of 2026, which is below Biogen Inc 's average return on assets, which stands at 11.92%.
ROA decreased relative to the period ending Jun 30 2026, due to the decline in net income.
However, within the Healthcare sector 198 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 1241, from total ROA ranking in the second quarter of 2026 at 1478.
Biogen Inc. a renowned leader in biopharmaceuticals, is embarking on an ambitious journey that could reshape the landscape of both its operational infrastructure and its contributions to the medical sciences. On March 24, 2025, the company unveiled plans for a new global headquarters and innovation hub situated in the heart of Kendall Square, Cambridge, Massachusetts, marking a pivotal moment in its 50-year history. A New Era in Kendall SquareWith its new headquarters located at 75 Broadway, Biogen aims to consolidate its presence in the vibrant Kendall Square area, a region known for its unparalleled collaboration between science, technology, and education. This consolidation reflects Biogen s commitment to enhancing its research and development (RandD) capabilities while maximizing synergies within its technical operations, commercial organizations, and innovation initiatives. By co-locating its teams, Biogen intends to foster an environment ripe for collaboration and innovation. As the global demography ages and the prevalence of neurodegenerative diseases peaks, the timing of this move is particularly significant. The new facility is projected to open in 2028, coinciding with the company’s 50th anniversary. This milestone not only underscores Biogen’s longstanding dedication to scientific breakthroughs but also positions the company to meet evolving health challenges head-on.
Biogen s Breakthrough Journey: Felzartamab s Promise in Tackling Antibody-Mediated Rejection in Kidney Transplants In a significant development for kidney transplant recipients, Biogen Inc. has announced that its investigational anti-CD38 monoclonal antibody, felzartamab, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA). This designation is awarded to therapeutic candidates that demonstrate preliminary clinical evidence suggesting a substantial improvement over existing treatments for serious or life-threatening conditions. The announcement, made on October 9, 2024, highlights felzartamab s potential specifically for the treatment of late antibody-mediated rejection (AMR) occurring in the absence of T-cell mediated rejection among kidney transplant recipients. With the rising demand for effective therapies to improve patient outcomes in organ transplantation, this designation offers a beacon of hope for both clinicians and patients navigating the complexities of post-transplant care.AMR is a major barrier to successful kidney transplantation, often leading to graft dysfunction and failure. Current treatment options for AMR are limited and not always effective, making the need for innovative therapies more pressing than ever. Felzartamab, by targeting CD38, could redefine the therapeutic landscape for patients experiencing AMR, potentially enhancing both graft longevity and patient quality of life.
The release of positive topline data by Biogen Inc. (Nasdaq: BIIB) from the Phase 2/3 DEVOTE study represents a crucial advancement in the treatment landscape for spinal muscular atrophy (SMA). Announced on September 4, 2024, these findings highlight the efficacy and safety of a higher dose regimen of nusinersen in treatment-naive, symptomatic infants. Promising Results from the DEVOTE Study:Biogen s innovative approach involved administering a rapid loading regimen of two 50 mg doses 14 days apart, followed by a higher maintenance regimen of 28 mg every four months. This differs from the approved regimen (SPINRAZA), thus offering a more intense initial treatment.The study s primary endpoint at six months was met successfully, demonstrating a statistically significant improvement in motor function in infants receiving the higher dose compared to a prespecified matched sham (untreated) control group from the ENDEAR study. This breakthrough provides renewed hope for infants suffering from SMA, potentially extending their motor functions and improving the quality of life at an earlier stage.
In a recent announcement, Eisai Co., Ltd. and Biogen Inc. revealed that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rejected the Marketing Authorization Approval (MAA) for lecanemab, a humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, as a treatment for early Alzheimer s disease (AD). This decision comes as an unfortunate setback in the search for effective therapies to address the devastating cognitive decline associated with AD. Biogen Inc., the key player behind lecanemab, has also experienced a decline in its asset returns. Let s delve into the details. Lecanemab Faces Regulatory Hurdles: The CHMP s negative opinion on lecanemab s MAA for treating mild cognitive impairment due to AD and mild AD is a significant setback for both Eisai Co., Ltd. and Biogen Inc. Lecanemab showed promising potential in targeting and reducing aggregated amyloid-beta plaques, a hallmark of AD pathology. However, based on the available clinical data, the CHMP concluded that the currently presented evidence was insufficient to demonstrate the antibody s effectiveness in treating early stages of the disease. Additional clinical studies and further evidence will be required before the therapy can attain regulatory approval in the European Union.
In a significant development for Alzheimer s disease patients, the drug LEQEMBI (Lecanemab) has been launched in China. China now becomes the third country after the United States and Japan to introduce this promising treatment for Alzheimer s disease. The launch of LEQEMBI in China is expected to provide new hope for patients and their families in combating this debilitating condition. Facts: 1. LEQEMBI (Lecanemab) is a drug developed by Biogen Inc, a renowned pharmaceutical company. 2. The drug has shown promising results in clinical trials in the United States and Japan. 3. LEQEMBI is designed to target amyloid-beta plaques, a characteristic feature of Alzheimer s disease. 4. The drug aims to slow down the progression of the disease and preserve cognitive function in patients. 5. In the first quarter of 2024, Biogen Inc reported a return on asset (ROA) of 4.44%, which falls below the company s average ROA of 12.56%.
Comment on BIIB's ROA in the fiscal year ending 2025
In the fiscal year 2025 Biogen Inc 's ROA decreased compared to previous year to 4.33 %, due to deterioration of net income -20.79 % to $1,292.90 million, from $1,632.20 million a year ago, as BIIB's assets were $29,871.40 million.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
